Banking & Finance

Analysis

WAFD shareholders bear near-term dilution risk until 2027, the first projected full-year of EPS accretion, making the stock vulnerable to selling pressure if regulatory approval timelines extend beyond 12 months. Bank mergers of this scale have faced 12-18 month regulatory review periods; any extension pushes the accretion date into 2028 and degrades the present value of the merger thesis. Investors pricing in 2027 accretion should monitor Fed and OCC application timelines as the primary leading indicator.

Analysis

Chinese state bank capital ratios improve near-term, but the 360bn yuan injection signals Beijing is managing latent stress rather than pursuing opportunistic expansion, which is structurally negative for private credit pricing in China. When sovereign capital is required at this scale to maintain adequacy, it implies non-performing asset pressure is larger than disclosed buffers suggest. Offshore investors holding subordinated or hybrid instruments of ICBC, CCB, ABC, and BOC should reassess loss-absorption risk, as the recapitalisation prioritises senior creditors at the expense of AT1 and Tier 2 instrument holders.